Cystic fibrosis

Six-year-old Tom Rolefson is prone to tonsillitis. When he's suffering from a sore, swollen throat, feeling uncomfortable and fatigued, he sometimes says to his twin sister, "Taylor, you're so lucky you don't have this."...  

Over 30 members of PTS competed in the contest with the entry fee being a donation to the Cystic Fibrosis Foundation to raise money for GREAT STRIDES, which is the Cystic Fibrosis Foundation’s largest and most successful national fundraising ...  

Chef Michael McDonald leads evening promising "a modern interpretation of the historic eight-course fine dining menu" of the R.M.S. Titanic. Participating chefs: Isabel Cruz (Barrio Star), Brian Malarkey (Gingham), Augustin "Augie" Saucedo (Sycuan Casino ...  

About 60,000 Europeans suffer from cystic fibrosis, a rare and life-threatening genetic disorder that is caused by a mutation of the CFTR gene, which regulates salt and water transport in the body. The CFTR mutation in cystic fibrosis patients allows too much salt and water into cells, which results in a build-up of thick, sticky mucus in the body's tubes and passageways that damage the lungs, digestive system and other organs. Symptoms...  

Investors hammered Vertex Pharmaceuticals yesterday after the Cambridge company revealed it had overstated results from a study of promising cystic fibrosis drugs. “This mistake is very disappointing,” Vertex CEO Jeffrey Leiden said on a conference call.  

Vertex Pharmaceuticals Inc released corrected data involving its cystic fibrosis treatments on Tuesday that lowered the number of patients who showed certain levels of improved lung function, sending its ...  

CAMBRIDGE, Mass. (TheStreet) -- Vertex Pharmaceuticals overstated the response to its two-drug cystic fibrosis therapy earlier this month due to a "misinterpretation" of interim data from a phase II study, the company acknowledged Tuesday. Fewer cystic fibrosis patients in the study saw their lung function improve by more than 5% following treatment with VX-809 and Kalydeco than was previously disclosed, Vertex said. Vertex shares slid 13% to...  

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) is under heavy pressure early Tuesday after correcting data about lung function from a Phase 2 trial of VX-809 and KALYDECO in cystic fibrosis patients sharply lower. Corrected data showed that 35% of patients ...  

Cystic fibrosis is a rare, life-threatening genetic disease affecting approximately 30,000 people in the United States and 70,000 people worldwide. Today, the median predicted age of survival for a person with is approximately 38 years but the median age ...  

Vertex Pharmaceuticals announced this morning that results of a drug combination in cystic fibrosis that have caused its stock to jump 86% since ... to $55.20 in pre-market trading. The data have been much-watched because the new combination ...  

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (forced expiratory volume in one second, FEV1) among adults with cystic...  

Doctors not only found a large hole in his heart but Gavin was also diagnosed with cystic fibrosis. Gavin’s father, Jason Steel said, “That combination of problems, the cystic fibrosis and the hole in the heart made it very difficult for ...  

Bart, a 16-year-old sophomore from Charlotte, N.C., describes this trick at length -- he calls it "cell phone mentalism" -- and a couple of versions are on YouTube. He says he tried 20 variations before he was happy. In the video, when the kids ...  

These mucoid type of Pseudomonas aeruginosa bacteria are coated in a slimy layer which makes them more difficult to treat with antibiotics and more difficult to clear with the body's own natural defences which leads to significant lung inflammation ...  

Concentrated saline therapy not effective in young children with cystic fibrosis. NIH-funded study demonstrates importance of conducting pediatric clinical trials Inhaling concentrated saline (salt water) mist does not reduce how often infants ...